Pharmacy benefit managers started popping up in the late 1960s as providers of claims processing and administrative services ...

Nearly 75% of Americans are classified as overweight or obese. Addressing our nation's health crisis requires much more than ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Not at all. Novo Nordisk's investigational weight loss therapy, CagriSema, combines semaglutide (the active ingredient in ...

Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Plenty of people want to lose weight in 2025, but here's why many may actually get there thanks to GLP-1 drugs.

GLP-1 receptor agonists (GLP-1RAs) on multiple fronts. They continued to expand into new indications, and provide their developers with both rich remuneration and scientific acclamation. There are now ...

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Whether this year’s big job commitments sink or swim will be known in time. But for now, let’s explore the dreams.

Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Mounjaro and Ozempic are both GLP-1 receptors that can be used to help people with diabetes. The treatments are also ...